Breast Biopsy Device Market to Reach $911.2 Million by 2024: Grand View Research, Inc.

News provided by

Grand View Research, Inc.

09 Aug, 2016, 10:15 BST

SAN FRANCISCO, August 9, 2016 /PRNewswire/ --

The breast biopsy device market is expected to reach USD 911.2 million by 2024, according to a new report by Grand View Research, Inc. The Breast biopsy device market is projected to grow at a productive rate in the next few years. The key factors supporting the industry's growth involve the rising awareness levels with regard to diagnostic procedures through cancer screening programs, global rise in breast cancers in women, and the high demand for less-invasive procedures. However, the degree of risk is directly proportional to the extent of procedure invasiveness. Biopsy causes pain and is a stressful procedure for patients, moreover, approximately 60% to 80% of breast biopsies in women result in a benign judgment. Therefore, women are encouraged to consult experts for a second opinion before undergoing a biopsy procedure, which is likely to hinder the growth of the market.

     (Logo: http://photos.prnewswire.com/prnh/20150105/723757 )

The test type segment is categorized into needle breast biopsies and open surgical biopsies. The former is further segmented into fine-needle aspiration, core-needle, and vacuum-assisted core biopsy. The fine-needle aspiration segment is estimated to hold the largest share for the year 2015 whereas the vacuum-assisted core biopsy segment is anticipated to witness a lucrative growth during the study period. The open surgical biopsy industry is sub-segmented into Incisional biopsy and Excisional biopsy.

On the basis of products, the industry is categorized into needles, tables, localization wires, and guidance systems. Additionally, the guidance systems segment of the industry is further categorized on the basis of imaging systems, such as ultrasound, mammography, and magnetic resonance imaging.

Browse full research report with TOC on "Breast Biopsy Device Market Analysis By Test Type (Needle Breast Biopsy: Fine-Needle Aspiration, Core-Needle Biopsy, Vacuum-Assisted Core Biopsy; Open Surgical Biopsy: Incisional Breast Biopsy), By Product (Biopsy Needles, Biopsy Tables, Localization Wires, Guidance Systems), By Guidance Type (Ultrasound-Guided, Mammography-Guided Stereotactic, Magnetic Resonance-Guided), By Region (U.S., Canada, Germany, UK, China, India, Brazil, Mexico, South Africa) And Segment Forecasts To 2024" at: http://www.grandviewresearch.com/industry-analysis/breast-biopsy-device-market

Further key findings from the study suggest: 

  • The Asia Pacific region is anticipated to witness the highest growth rate, with a CAGR of around 12.6% during the forecast period. The high frequencies of breast cancer prevailing in women as well as the increase in awareness of cancer screening programs are the factors fueling the market growth.
  • North America accounts for the largest market share, followed by the European market. The heightened awareness about breast cancer that advocate regular checkups and screening programs along with the demand for accurate and minimally caustic procedures are factors that are responsible for the rapid market growth.
  • The mammography-guided stereotactic segment is estimated to hold the largest market share followed by the magnetic resonance imaging-guided category. The rise in demand for rapid and precise diagnostic imaging tools in determining the exact location of the tumor or lump in the breast area is one of the major factors driving the growth of this industry
  • On the basis of test type, the needle-based biopsy segment accounts for the largest share; this is mainly due to the high demand for minimally invasive procedures. On the other hand, the open surgical biopsies have a probability to witness a decline in the market over the next few years due to the relatively high invasiveness and the risks involved with the procedure.
  • Some major players in this industry include Becton, Dickenson and Company (BD), C.R Bard, Inc., Devicor medical, Inc., and Hologic, Inc., among others.

Grand View Research has segmented the global breast biopsy devices market on the basis of test type, guidance, product, and region: 

  • Breast Biopsy Devices Market By Test Type Outlook (Revenue, USD Million, 2013 - 2024) 
    • Needle breast biopsies
    • Fine-needle aspiration
    • Core-needle aspiration
    • Vacuum-assisted core biopsy
    • Open surgical biopsies
    • Incisional breast biopsy
    • Excisional breast biopsy
  • Breast Biopsy Devices Market By Product Outlook (Revenue, USD Million, 2013 - 2024) 
    • Biopsy needles
    • Biopsy tables
    • Localization wires
    • Guidance systems
    • Others
  • Breast Biopsy Devices Market By Guidance Type Outlook (Revenue, USD Million, 2013 - 2024) 
    • Ultrasound-guided
    • Mammography-guided stereotactic
    • Magnetic resonance-guided
    • Others
  • Breast biopsy device market Regional Outlook (Revenue, USD Million, 2013 - 2024) 
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
    • Asia Pacific
      • China
      • India
    • Latin America
      • Brazil
      • Mexico
    • Middle East and Africa
      • South Africa

 Browse related reports by Grand View Research: 

About Grand View Research: 

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Read Our Blogs - mediafound.org, grandviewresearch.com/blogs/healthcare

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: http://www.grandviewresearch.com  

SOURCE Grand View Research, Inc.